OSE Immunotherapeutics Seeks Partner For Lead Drug
Executive Summary
Emerging Company Profile: Alexis Peyroles, chief operating officer of OSE Immunotherapeutics outlines the 2016-founded company's plans for commercializing its lead drug, Tedopi (OSE-2102).